These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 34800987)

  • 1. The association between serum ferritin levels and malignant intraductal papillary mucinous neoplasms.
    Zhuge X; Zhou H; Chen L; Chen H; Chen X; Guo C
    BMC Cancer; 2021 Nov; 21(1):1253. PubMed ID: 34800987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas.
    Kim JR; Jang JY; Kang MJ; Park T; Lee SY; Jung W; Chang J; Shin Y; Han Y; Kim SW
    J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):699-707. PubMed ID: 26178866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors Associated With Invasive Intraductal Papillary Mucinous Carcinoma of the Pancreas.
    Hirono S; Kawai M; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Ueno M; Yanagisawa A; Yamaue H
    JAMA Surg; 2017 Mar; 152(3):e165054. PubMed ID: 28122068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison between intraductal papillary neoplasms of the biliary tract (BT-IPMNs) and intraductal papillary mucinous neoplasms of the pancreas (P-IPMNs) reveals distinct clinical manifestations and outcomes.
    Minagawa N; Sato N; Mori Y; Tamura T; Higure A; Yamaguchi K
    Eur J Surg Oncol; 2013 Jun; 39(6):554-8. PubMed ID: 23506840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Threshold of Main Pancreatic Duct Diameter in Identifying Malignant Intraductal Papillary Mucinous Neoplasm by Magnetic Resonance Imaging.
    Zhang H; Cao Y; Ren S; Guo K; Zhang Y; Lin T; Wang Y; Chen X; Wang Z
    Technol Cancer Res Treat; 2023; 22():15330338231170942. PubMed ID: 37078135
    [No Abstract]   [Full Text] [Related]  

  • 6. Decision making for pancreatic resection in patients with intraductal papillary mucinous neoplasms.
    Xu B; Ding WX; Jin DY; Wang DS; Lou WH
    World J Gastroenterol; 2013 Mar; 19(9):1451-7. PubMed ID: 23539521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Main pancreatic duct involved IPMN without high-risk factors: how to judge the degree of malignancy based on MPD dilation?
    Zhu Y; Mao Y; Wang J; Wang Z; Chen X
    Medicine (Baltimore); 2024 Aug; 103(33):e39323. PubMed ID: 39151506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The natural history of main duct-involved, mixed-type intraductal papillary mucinous neoplasm: parameters predictive of progression.
    Roch AM; Ceppa EP; Al-Haddad MA; DeWitt JM; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
    Ann Surg; 2014 Oct; 260(4):680-8; discussion 688-90. PubMed ID: 25203885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Threshold of main pancreatic duct for malignancy in intraductal papillary mucinous neoplasm at head-neck and body-tail.
    Zhou H; Li X; Wang Y; Wang Z; Zhu J; Wang Z; Chen X
    BMC Gastroenterol; 2022 Nov; 22(1):473. PubMed ID: 36402960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of invasive carcinoma in branch type intraductal papillary mucinous neoplasms of the pancreas.
    Kanno A; Satoh K; Hirota M; Hamada S; Umino J; Itoh H; Masamune A; Asakura T; Shimosegawa T
    J Gastroenterol; 2010 Sep; 45(9):952-9. PubMed ID: 20383536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nomogram to predict malignancy in branch duct type intraductal papillary mucinous neoplasms.
    Xu Y; Xie C; Gao Z; Zhang M; Zhan M
    Medicine (Baltimore); 2022 Sep; 101(38):e30627. PubMed ID: 36197166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proposed Nomogram Predicting the Individual Risk of Malignancy in the Patients With Branch Duct Type Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Jang JY; Park T; Lee S; Kim Y; Lee SY; Kim SW; Kim SC; Song KB; Yamamoto M; Hatori T; Hirono S; Satoi S; Fujii T; Hirano S; Hashimoto Y; Shimizu Y; Choi DW; Choi SH; Heo JS; Motoi F; Matsumoto I; Lee WJ; Kang CM; Han HS; Yoon YS; Sho M; Nagano H; Honda G; Kim SG; Yu HC; Chung JC; Nagakawa Y; Seo HI; Yamaue H
    Ann Surg; 2017 Dec; 266(6):1062-1068. PubMed ID: 27607098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Main duct and mixed type intraductal papillary mucinous neoplasms without enhancing mural nodules: Duct diameter of less than 10 mm and segmental dilatation of main pancreatic duct are findings support surveillance rather than immediate surgery.
    Kim TH; Song TJ; Lee SO; Park CH; Moon JH; Pih GY; Oh DW; Woo SM; Yang YJ; Kim MH
    Pancreatology; 2019 Dec; 19(8):1054-1060. PubMed ID: 31611130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI-Based Pancreatic Atrophy Is Associated With Malignancy or Invasive Carcinoma in Intraductal Papillary Mucinous Neoplasm.
    Lin T; Chen X; Liu J; Cao Y; Cui W; Wang Z; Wang C; Chen X
    Front Oncol; 2022; 12():894023. PubMed ID: 35719938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of serum carbohydrate antigen 19-9 in malignant intraductal papillary mucinous neoplasms.
    Xu B; Zheng WY; Jin DY; Ding WX; Lou WH; Ramsohok L
    World J Surg; 2011 May; 35(5):1103-9. PubMed ID: 21416173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of whole-lesion ADC histogram metrics for assessing the malignant potential of pancreatic intraductal papillary mucinous neoplasms (IPMNs).
    Hoffman DH; Ream JM; Hajdu CH; Rosenkrantz AB
    Abdom Radiol (NY); 2017 Apr; 42(4):1222-1228. PubMed ID: 27900458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum N-glycan profiles in patients with intraductal papillary mucinous neoplasms of the pancreas.
    Akimoto Y; Nouso K; Kato H; Miyahara K; Dohi C; Morimoto Y; Kinugasa H; Tomoda T; Yamamoto N; Tsutsumi K; Kuwaki K; Onishi H; Ikeda F; Nakamura S; Shiraha H; Takaki A; Okada H; Amano M; Nishimura S; Yamamoto K
    Pancreatology; 2015; 15(4):432-8. PubMed ID: 26052067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbohydrate antigen 125 supplements carbohydrate antigen 19-9 for the prediction of invasive intraductal papillary mucinous neoplasms of the pancreas.
    Qian Y; Gong Y; Luo G; Liu Y; Wang R; Zou X; Deng S; Lin X; Chen Y; Wang X; Yu X; Cheng H; Liu C
    World J Surg Oncol; 2022 Sep; 20(1):310. PubMed ID: 36155113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas.
    Fritz S; Hackert T; Hinz U; Hartwig W; Büchler MW; Werner J
    Br J Surg; 2011 Jan; 98(1):104-10. PubMed ID: 20949535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-operative nomogram predicting malignant potential in the patients with intraductal papillary mucinous neoplasm of the pancreas: focused on imaging features based on revised international guideline.
    Hwang JA; Choi SY; Lee JE; Kim SS; Lee S; Moon JY; Heo NH
    Eur Radiol; 2020 Jul; 30(7):3711-3722. PubMed ID: 32095876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.